Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.14
Price to sales ratio
4.49

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2891
KYTX
Kyverna Therapeutics, Inc. - Common Stock
8.64 USD+0.35%+4.85%+15.20%+121.54%534.33 M USD
2892
ENTX
Entera Bio Ltd. - Ordinary Shares
3.08 USD-3.45%-4.35%-4.35%+54.00%533.28 M USD
2915
PRLD
Prelude Therapeutics Incorporated - Common Stock
6.34 USD-3.35%-3.35%+36.64%+391.47%505.95 M USD
2918
CCCC
C4 Therapeutics, Inc. - Common Stock
4.10 USD-3.30%0.00%+18.84%+62.06%504.40 M USD

Frequently asked questions about Editas Medicine, Inc. Common Stock

What is the Editas Medicine, Inc. Common Stock stock price today?

The current price of Editas Medicine, Inc. Common Stock (EDIT) is 3.30. Over the past 24 hours, the stock has changed by +3.77%. Follow the EDIT chart for real-time price dynamics.

What is the stock ticker of Editas Medicine, Inc. Common Stock?

Editas Medicine, Inc. Common Stock trades under the ticker EDIT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Editas Medicine, Inc. Common Stock stock going up?

EDIT has changed by +10.74% over the last week, +26.92% over the last month, and +24.53% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Editas Medicine, Inc. Common Stock?

Editas Medicine, Inc. Common Stock currently has a market capitalization of 506.81 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Editas Medicine, Inc. Common Stock earnings last quarter?

Last quarter, Editas Medicine, Inc. Common Stock reported earnings of -0.15 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Editas Medicine, Inc. Common Stock revenue for the last quarter?

Editas Medicine, Inc. Common Stock reported quarterly revenue of 11.89 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Editas Medicine, Inc. Common Stock net income for the last quarter?

Editas Medicine, Inc. Common Stock reported net income of -18.23 M for the last quarter. The previous quarter showed -24.98 M, which means net income changed by +27.03%.

How many employees does Editas Medicine, Inc. Common Stock have?

As of the latest available data, Editas Medicine, Inc. Common Stock has 87 employees. Workforce size can provide additional context about the company's scale and operations.

What is Editas Medicine, Inc. Common Stock EBITDA?

Editas Medicine, Inc. Common Stock EBITDA is -18.14 M, and its EBITDA margin is -152.55%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Editas Medicine, Inc. Common Stock stock?

You can buy Editas Medicine, Inc. Common Stock (EDIT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Editas Medicine, Inc. Common Stock stock?

Investing in Editas Medicine, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the EDIT chart and related analysis on metatrader.com as part of your research.

Editas Medicine, Inc. - Common Stock

Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

News